Amplify Weight Loss Drug & Treatment ETF (THNR)

THNR Holdings Information

THNR is an equity ETF with a total of 22 individual holdings. The top holdings are Novo Nordisk stock at 14.80%, Eli Lilly and Company at 12.64%, Regeneron Pharmaceuticals at 6.25%, Arrowhead Pharmaceuticals at 6.22%, and Amgen at 5.98%.

• Total Holdings: 22
• Top 10 Percentage: 71.10%
• Asset Class: Equity
• ETF Category: Health
• Assets: 4.16M
• PE Ratio: 18.74

Top 25 Holdings

As of May 14, 2026

Filter results

No.	Symbol	Name	% Weight	Shares
1	NVO	Novo Nordisk A/S	14.80%	13,608
2	LLY	Eli Lilly and Company	12.64%	529
3	REGN	Regeneron Pharmaceuticals, Inc.	6.25%	369
4	ARWR	Arrowhead Pharmaceuticals, Inc.	6.22%	3,287
5	AMGN	Amgen Inc.	5.98%	749
6	TYO: 4519	Chugai Pharmaceutical Co., Ltd.	5.59%	4,600
7	HKG: 1801	Innovent Biologics, Inc.	5.26%	20,000
8	SWX: ROP	Roche Holding AG	4.95%	510
9	MRK	Merck & Co., Inc.	4.75%	1,763
10	LON: AZN	AstraZeneca PLC	4.67%	1,063
11	PFE	Pfizer Inc.	4.65%	7,606
12	ABBV	AbbVie Inc.	4.54%	907
13	HKG: 1093	CSPC Pharmaceutical Group Limited	4.34%	180,000
14	TYO: 4507	Shionogi & Co., Ltd.	4.30%	9,300
15	SRRK	Scholar Rock Holding Corporation	2.44%	2,005
16	VKTX	Viking Therapeutics, Inc.	2.12%	2,818
17	CPH: ZEAL	Zealand Pharma A/S	1.85%	1,604
18	GPCR	Structure Therapeutics Inc.	1.64%	1,738
19	JNGHF	Jiangsu Hengrui Pharmaceuticals Co Ltd Ordinary Shares - Class H	1.25%	6,200
20	KRX: 128940	Hanmi Pharm. Co., Ltd.	1.13%	158
21	AGPXX	Short-Term Investment Trust - Invesco Government & Agency Portfolio	0.89%	37,634
22	n/a	OTHER ASSETS AND LIABILITIES	-0.26%	139,891,295